Evidence suggests that psilocybin-assisted therapy for those who have not responded to standard interventions may be beneficial.
|Articles|June 1, 2004
- Volume 0 0
Exam
Advertisement
Articles in this issue
over 22 years ago
dual pathover 22 years ago
Managed Care Commentary:MCOs face new challengesover 22 years ago
Phytosterols may play role in atherosclerosisover 22 years ago
Dual pathway inhibition: Attacking cholesterol on two frontsover 22 years ago
Future Goals, Targets, and Treatments of DyslipidemiaAdvertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Weight-based norepinephrine dosing did not improve time to goal MAP, and median dose was similar compared with non–weight-based dosing in patients with septic shock.
The panelists emphasized that selecting a therapy is only one step toward improving outcomes for patients with heart failure.
Pharmacists can educate patients about staying up to date on immunizations and discuss fall prevention strategies.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
2
New Data Reshape Nonstatin Lipid Therapy Choices
3
After 180 Years, Multiple Myeloma Gets a Definition of Cure
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5